Lung Cancer

Lorlatinib Improves PFS Compared to Crizotinib for Patients with ALK-Positive NSCLC
August 06, 2020

Pfizer Inc.’s phase 3 CROWN trial examining lorlatinib to treat patients with ALK-positive NSCLC met its primary end point of improving progression-free survival when compared to crizotinib.

Global Lung Cancer Burden Suggests Need for Tailored Measures
July 31, 2020

Researchers suggested that based on their findings, increased efforts are needed to implement intervention strategies tailored to local settings to effectively decrease the global lung cancer burden and reduce health inequality.

Radiomics Model May Predict Survival Outcomes Among Patients Diagnosed with Lung Cancer
July 31, 2020

This study created and assessed a parsimonious radiomic model that was able to identify a vulnerable subset of screen-detected lung cancers that are associated with poor outcome.